FDA Panel Recommends Diabetes Drugs Highlight Heart Failure Risk
FDA warns of potential issues from diabetes drugs Onglyza, Kombiglyze, and Nesina.
FDA warns of potential issues from diabetes drugs Onglyza, Kombiglyze, and Nesina.
An FDA advisory panel recommends adding a warning about the potential risk for heart failure to the labels of 2 of AstraZeneca’s diabetes treatments, saxagliptin (Onglyza) and saxagliptin/metformin (Kombiglyze), as well as Takeda's diabetes drug, alogliptin (Nesina).
Still, the regulatory panelists said the 3 dipeptidyl peptidase-4 inhibitors have acceptable heart safety profiles. The panel’s decisions were partially based on the findings of a heart study involving approximately 16,000 patients that did not demonstrate an increased risk of heart attack with Onglyza compared with placebo.
However, data from an AstraZeneca trial suggested the use of the drug was associated with a higher rate of heart failure. Additionally, a preliminary FDA review determined Onglyza was associated with an increased risk of all-cause death.
While the panelists were concerned by these findings, they could not identify a common cause of death. A separate FDA review of Nesina found the drug was associated with an increase in hospitalizations for heart failure compared with placebo, though the difference was not deemed statistically significant.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
Effectively Managing Immunizations in the Long-Term Care SettingSeptember 18th 2025
Creating a Culture of Quality in Fast-Melt Tablet DevelopmentSeptember 18th 2025
Advise Patients About Self-Care Measures to Treat Mild to Moderate GI IssuesSeptember 18th 2025
